James Price, Foundation’s President and CEO, and Dr. Janet Rossant, Interim Director of the Ontario Institute for Regenerative Medicine and immediate past president of the International Society for Stem Cell Research, co-authored the article, headlined ‘Make Canada a magnet for stem cell trials’. Exploring the impact of experimental stem cell treatments abroad, the piece makes the case for Canada to build on its expertise in stem cell research and development to become the location of choice for high quality clinical trials.
“The real impact of many of the experimental stem cell treatments offered abroad is a question mark.” said the authors. “A better solution is made-in-Canada treatments. Give Canadians access to safe, cutting-edge and rigorously reviewed stem cell clinical trials here in Canada. Once fully proven, these treatments would be available across the country.” they added.
Although several stem cell-related clinical trials are already under way in Canada (you can read about the recent announcement of a new stem cell trial for MS on our blog), there is the potential to do more.The Strategy & Action Plan will see Canada lead the way to bringing five to 10 new safe and proven therapies to the clinic within 10 years.
“Canadians should not need to travel abroad where experimental treatments are unproven and could carry serious health risks. We all want our loved ones to have access to the best care available when they need it. So let’s get this done.”
You can read the full version of the Globe and Mail article here.